ATX-IN-2

• Description:

  ATX-IN-2 (Compound 25) is an orally active and potent ATX inhibitor with an IC50 value of 3.27 nM. ATX-IN-2 reduces lysophosphatidic acid (LPA) secretion. ATX-IN-2 is promising for research of ATX-mediated diseases, such as inflammation, pulmonary fibrosis[1].

• UNSPSC:

  12352005

• Target:

  Phosphodiesterase (PDE)

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  O=C(N1CC2(COC2)C1)C3(CC3)N4CCN(C(S5)=NN6C5=NC(CC)=C6N(C([2H])([2H])[2H])C7=NC(C8=CC=C(F)C=C8)=C(C#N)S7)CC4

• Molecular Formula:

  C30H29D3FN9O2S2

• Molecular Weight:

  636.78

• References & Citations:

  [1]Wang H, et al. Successive structural optimization of Ziritaxestat culminates in the discovery of orally bioavailable and in vivo potent imidazothiadiazole derivative for treating ATX-driven diseases. Eur J Med Chem. 2025 May 21;295:117769.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [3076224-81-9]